This study‐level meta‐analysis of five randomised controlled trials aimed to provide comprehensive evidence on the efficacy and safety of orforglipron, a novel non‐peptide oral GLP‐1 receptor agonist, in obese patients with or without type 2 diabetes mellitus (T2DM). Here, GLP1R is linked to type 2 diabetes mellitus.